- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine, oxaliplatin, Radiation
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pancreas Adenocarcinoma
- Interventions
- Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Pancreas Cancer
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 3
- States / cities
- DeKalb, Illinois • Geneva, Illinois • Warrenville, Illinois
- Conditions
- Surgical Site Infection, Pancreatic Neoplasms, Pancreatic Cancer, Chemotherapy Effects, Chemoradiation, Surgical Wound, Wound Complication
- Interventions
- Prevena Peel & Place Dressing, Standard Closure of the Surgical Incision
- Device · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
- Drug · Radiation · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
- Interventions
- daraxonrasib
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 22 more
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Interventions
- Paclitaxel Protein Bound (Abraxane)
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Pancreatic Neoplasms
- Interventions
- GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pancreatic Cancer
- Interventions
- AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D), mKRASvax
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colon Cancer, Pancreas Cancer, Digestive Cancer
- Interventions
- CEND-1, Panitumumab, Folfirinox
- Drug
- Lead sponsor
- Anup Kasi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
- Interventions
- Pembrolizumab, Defactinib
- Drug
- Lead sponsor
- Lei Zheng
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • San Antonio, Texas
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, oxaliplatin, protein expression analysis, proteomic profiling, diagnostic laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- PTM-101
- Drug
- Lead sponsor
- PanTher Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Detroit, Michigan • Lake Success, New York + 3 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- LDE225-600mg, Gemcitabine, nab-paclitaxel, LDE225-400mg, LDE225-800mg
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- Durvalumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 101 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pancreas Neoplasm Malignant Resectable
- Interventions
- Folfox6, Gemcitabine, Radiation Therapy, Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
- Drug · Radiation · Procedure
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Borderline-resectable Pancreatic Cancer
- Interventions
- Point-of-care Portable Perfusion Phantom (P4)
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Columbus, Ohio
- Conditions
- Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
- Interventions
- Neoadjuvant gemcitabine, capecitabine, and docetaxel, Gemcitabine, capecitabine, docetaxel followed by radiotherapy
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer
- Interventions
- ELI-002 7P, Tislelizumab, mFOLFIRINOX
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, Oxaliplatin, Erlotinib
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Interventions
- Nab paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
- Interventions
- Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- 5 Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more